Neurogene Inc.
NGNE
$20.02
$0.784.05%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -100.00% | -100.00% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.00% | -100.00% | -- | -- | -- |
| Cost of Revenue | 20.90% | 29.77% | 36.95% | 37.01% | 33.47% |
| Gross Profit | -22.87% | -32.08% | -35.01% | -34.93% | -31.33% |
| SG&A Expenses | 45.27% | 61.14% | 86.72% | 102.10% | 79.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.94% | 37.29% | 48.07% | 50.12% | 42.49% |
| Operating Income | -28.49% | -39.14% | -46.56% | -48.45% | -40.77% |
| Income Before Tax | -59.88% | -77.27% | -97.36% | -106.91% | -4.50% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -59.88% | -77.27% | -97.36% | -106.91% | -4.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -59.88% | -77.27% | -97.36% | -106.91% | -4.50% |
| EBIT | -28.49% | -39.14% | -46.56% | -48.45% | -40.77% |
| EBITDA | -30.02% | -41.36% | -49.42% | -51.60% | -43.70% |
| EPS Basic | -105.27% | -109.25% | -120.71% | 30.90% | 187.02% |
| Normalized Basic EPS | 83.54% | 92.35% | 94.68% | 96.08% | 72.15% |
| EPS Diluted | -1,484.65% | 86.38% | 92.38% | 94.93% | 99.71% |
| Normalized Diluted EPS | -0.71% | 87.85% | 92.86% | 95.16% | 95.45% |
| Average Basic Shares Outstanding | 60.74% | 124.63% | 303.31% | 3,471.62% | 635.91% |
| Average Diluted Shares Outstanding | 21.42% | 52.10% | 111.87% | 277.22% | 874.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |